• Male or female, age ranging from 18 to 70 years old (excluding 70 years old);

• body weight ≥45 kg;

• Histologically or cytologically confirmed diagnosis of malignant solid tumor;

• Solid tumor patients who receive a 3-week chemotherapy regimen have been evaluated as high-risk for FN or evaluated as having moderate risk for FN, but with an increased risk factor for neutropenia associated with the chemotherapy regimen;(The risk assessment of FN in tumor chemotherapy is based on Chinese Society of Clinical Oncology (CSCO) guidelines for standardized management of tumor chemoradiotherapy related neutropenia(2021 edition) and Consensus on clinical diagnosis, treatment, and prevention of chemotherapy-induced neutropenia in China(2023 edition);

• Karnofsky Performance Scale(KPS) score≥70;

• The total number of white blood cells and absolute value of neutrophils before chemotherapy should not be lower than normal values: WBC ≥ 3.5 × 109/L, ANC ≥ 1.5 × 109/L;

• Subject has a life Expectation of at least 6 month；

• Subjects voluntarily and strictly comply with the research protocol requirements and sign a written informed consent for.